What Can You Expect in 2026?
The 3rd GLP-1 Summit is the essential global forum to master the next generation of therapeutics.
With the GLP-1 pipeline entering a fiercely competitive phase where differentiation is the sole commercial driver, this summit is your strategic mandate to push beyond monotherapy and secure your 2026 market position.
We’ll dive deep into multi-agonist combinations, next-generation tolerability, adaptive clinical trial design, and the untapped potential in emerging indications, including neurodegenerative disease from industry giants including Eli Lilly, AstraZeneca and Sanofi.
Don’t miss the opportunity to forge crucial collaborations and be part of the solution defining the future of GLP-1 treatments.
Unmissable Event Highlights
Unlock the next generation of GLP-1 combinations and gain competitive intelligence on multi-agonist and combination therapies designed to enhance efficacy, minimize muscle loss, and improve body composition for superior patient outcomes
Discover high-value indication expansion and explore the next frontier of GLP-1 development beyond obesity through exclusive data on clinical programs targeting liver, renal and cardiometabolic disorders alongside neurological diseases and women’s health conditions
Master alternative delivery and patient adherence through dedicated sessions focused on overcoming the challenges of administration through oral programs and less frequent dosing strategies for long-term patient success
Benchmark against industry titans and innovators and hear directly from the companies leading the pipeline, including experts from Eli Lilly, Constructive Bio and Regeneron
Attending Companies Include